Format

Send to

Choose Destination

Crohn's Disease: Management in Adults, Children and Young People.

Editors

National Clinical Guideline Centre (UK).

Source

London: Royal College of Physicians (UK); 2012 Oct.
National Institute for Health and Clinical Excellence: Guidance .

Excerpt

This guideline intends to show the place of both new and established treatments in the wider care pathway for Crohn's disease. This will be useful for clinicians and people with Crohn's disease because new drugs have been licensed for Crohn's disease in the last decade. The guideline also deals with those medications which are unlicensed for treatment of the condition, but which have been used in this way (off-label) for many years and their role is recognised in other NICE documents as well as the British National Formulary. They include azathioprine, mercaptopurine and methotrexate. The guideline aims to help improve the care offered to people with Crohn's disease and provide information about the clinical and cost effectiveness of potential care pathways. Management of Crohn's disease in specific populations (for example, in pregnancy) may require special consideration.

Copyright © October 2012, National Clinical Guideline Centre.

Support Center